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Abstract 
The aim of the present study was to investigate deviations between prescribed from delivered dose 
for cervical cancer patients treated at Ocean Road Cancer Institute using Equinox 80 Tele-cobalt 
machine. In this work, anterior-posterior (AP) and posterior-anterior (PA) fields using Source-to-
Axis Distance (SAD) technique was used. Measurements of entrance doses were taken using 
calibrated diode detector in three groups of patients. In group 1, only 15 patients out of 31 curative 
intent patients received doses lower than ± 5% of 2 Gy as compared to the prescribed dose. In 
group 2, 1 measurement was done for 9 patients who received palliative single dose of 10 Gy and 
2 patients out of 9 received doses within the range of ± 5% of the prescribed dose. In group 3, 1 
daily measurement was done for 12 patients who were prescribed a curative dose of 50 Gy in 25 
fractions. The maximum observed deviation was + 25.08%, while that of minimum was – 0.59%. 
Since significant deviations between prescribed and delivered doses exist, there is a need to 
conduct another study using both patient and machine related factors to refine the problem of high 
dose deviations among the patients.  
 
Keywords: Tele-cobalt machine, in-vivo dosimetry, measured and delivered dose, cervical 
cancer, diode detector. 
 
Introduction 
External beam radiation therapy plays a 
vital role in the management of carcinoma of 
the cervix and is the standard treatment of 
choice of this type of cancer (Srinivas et al. 
2014). The ability to deliver the precise 
tumour dose in external beam radiation 
therapy depends on several factors; the most 
significant include exact dose calibration, 
accurately determined depth dose, off-axis 
dose characteristics, and knowledge of the 
precise patient geometry used during 
irradiation (Yorke et al. 2005). The ultimate 
check of the real dose delivered to a patient in 
radiotherapy can only be achieved by using 
in-vivo dosimetry (Tunio et al. 2011) and 
serves as an essential part of a quality 
assurance program. Beside the importance of 
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in-vivo dosimetry in detecting clinically 
relevant differences in radiation therapy, it is 
not carried out on routine basis at Ocean Road 
Cancer Institute (ORCI). It is therefore, this 
study aimed to use in-vivo dosimetry using 
diode detector to investigate the percentage 
dose deviations between prescribed and 
delivered doses for cervical cancer patients 
who received external beam radiotherapy 
using Equinox 80 tele-cobalt machine (from 
Best Theratronics, Ottawa, Canada) at Ocean 
Road Cancer Institute (ORCI).  
 
Materials and Methods  
Ethical consideration  
Ethical clearance was obtained from the 
University of Dar es Salaam Research Ethics 
Committee (UDSM-REC). The permission to 
conduct this study was obtained from 
authorities of ORCI through its research, 
publication and ethics committee before the 
commencement of this study. 
 
Dose measurements 
All entrance dose measurements were 
performed on patients receiving pelvic 
radiotherapy for cervical cancer. This work 
concentrated only on cervical cancer because 
more than 34% of all new cancer cases at 
ORCI fall in this category (Amour et al. 
2019). Data of cervical cancer patients’ doses 
was obtained from 3
rd
 September 2018 to 20
th
 
February 2019. The prescribed dose for 
curative intent for cervical cancer patient at 
ORCI is 2 Gy per fraction, while that of 
palliative intent patients is 10 Gy per fraction. 
Therefore, the total prescribed treatment dose 
of curative intent patient which is more 
relevant for curability is 50 Gy in 25 
fractions. According to ORCI treatment 
protocol, the delivered dose was obtained by 
specifying both machine and patient’s 
parameters that were used during treatment 
planning. Since ORCI uses Co-60 teletherapy 
machine, therefore, Tera six Simulator which 
was installed in 2011 by UJP PRAHA is used 
for taking two-dimension (2-D) images to 
help in treatment planning procedures. Since 
it is not possible to insert radiation detector in 
patients’ body, dose delivered to the tumour 
was estimated using entrance dose (Dent). 
Each patient was then placed in supine 
position on the treatment coach and diode was 
placed at the centre of the radiation field on 
the patient skin in order to measure the 
entrance dose. For the entry point, the 
entrance dose Dent which is defined as the 
dose at dmax from the incident plane on the 
axis of the beam was calculated using 
Equation (1) (Heukelom et al. 1991): 
icdent CFFRD  ..   (1)
 
where;  Rd is diode reading, Fc is calibration 




    
 
Calibration of diode detector 
Dosimetric diode IVD, manufactured by 
Sun Nuclear Corporation, Melbone, FL, USA 
model 1131 was calibrated against an 
ionization chamber (model W- 30001 with 
serial number 1205) connected to the 
electrometer (model UNIDOS with serial 
number 20359 from PTW Freiburg) during 
the calibration process. The methodology 
used for calibration of diode followed the 
IAEA, TRS-398 protocols for absorbed dose 
determination in external beam radiotherapy. 
By using Source-to-Axis Distance (SAD) 
technique, measurements were taken while 
the diode placed on the top surface of water 
phantom (dimensions: 30 cm × 30 cm × 30 
cm) was kept at 70 cm in such a way that 
source of Equinox 80 teletherapy unit to 
ionization chamber distance was 80 cm. Three 
readings are taken each for one minute for 
reference field size of 10 cm × 10 cm. The 
absorbed dose to water at reference depth was 
then obtained by using Equation (2), (IAEA, 
2000): 
                     (2) 
where;  
MQ is the reading of the dosimeter 
positioned in accordance with the 
reference conditions given by the 
manufacturer.  
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NDW  is absorbed dose to water calibration 
factor for given electrometer and 
ionization chamber. 
K pol is a factor to correct for any 
departure of the reading due to 
changing the polarizing voltage from 
its value at calibration. 
Ks  is a factor to correct for the lack of 
saturation due to recombination. 
KQ is the correction factor for energy 
and for Co-60 is taken as 1. 
K TP is a factor to correct for departure of 
air density from reference conditions. 
 
Since the chamber was kept at a depth of 10 
cm which is the reference point, the output 
readings obtained from equation 2 would be 
at 10 cm depth. To obtain the output at d max 
as a function of field size, the above formula 
was divided by tissue-air-ratio at 10 cm depth 
for SAD. 
This was done to check for the safety purpose 
before the dose is delivered to the patients. 
 
Treatment time 
Treatment time required to deliver a 
prescribed dose (T) for each patient was 










where: Dp and Dr represent prescribed dose 
and dose rate, respectively, while Sf is total 
scatter factor and TAR is the tissue-air-ratio 
obtained from Storchi and van Gasteren 
(1996) and Wamied (1999), respectively. 
The control console was used to set the 
irradiation time for each patient and diode 
recorded the respective readings. Gantry and 
collimator angles were rotated and set at zero 
degrees for entrance dose measurements in 
order to match with the obtained simulation 
parameters. The combination of anterior-
posterior and posterior-anterior open beam 
two fields’ Source-to-Axis Distance (SAD) 
technique was used in this work for treatment 
of both curative and palliative intent patients. 
This procedure was done for 43 curative 




A total of 52 cervical cancer patients of 
different depths and field sizes were treated at 
ORCI for both curative and palliative intent 
cases. The numbers of patients with curative 
intent were 43 with prescribed dose of 2 Gy 
per fraction. 12 patients out of 43 (referred to 
as group 3) were treated using 25 fractions in 
order to complete a total prescribed dose of 50 
Gy. Out of 52 cervical cancer patients, there 
were only 9 (group 2) palliative patients with 
prescribed dose of 10 Gy per fraction. With 
this prescription, a single dose of 10 Gy by 
delivering 5 Gy in anterior-posterior and 
posterior-anterior (AP and PA) fields were 
given for all palliative patients. The diode 
dose reading used to calculate the entrance 
dose for fraction 1 for 31 patients are 
compared with prescribed dose calculated 
using patient’s and machine parameters 
(depth and treatment field). For the sake of 
comparison, the percentage deviations of 
entrance doses from prescribed doses are 
listed in Table 1. From the literature, 
curability requires the percentage deviation to 
be within ± 5% (ICRU 2016, IAEA 2000, 
Thwaites 2013). According to this 
specification, only 15 patients (48%) out of 31 
listed in Table 1 were expected to have 
relatively favourable prognosis because the 
deviations ranged from 0.73% for patient # 7 
and patient # 12 to 4.35% for patient # 14.  
Like in the case of curative intent 
patients, Table 2 shows the percentage 
deviations between entrance and prescribed 
doses for 9 palliative intent patients each 
treated with a single dose of 10 Gy.  
In principle, curability of cancer of the 
cervix depends on the overall dose delivery 
accuracy. This has been computed by 
summing delivered doses of each fraction. 
The comparison of deviations of total 
prescribed and total delivered doses for 
curative patients are presented in Table 3. 
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According to the earlier dose delivery 
accuracy specification, only 4 out of 12 
patients ( 33%) were expected to have 
favourable prognosis because their deviations 
ranged from –0.59% for patient # 49 to 4.94% 
for patient # 41. On the other hand, 8 patients 
were expected to have poor prognosis because 
of large range of percentage dose deviations. 
For patient # 45, the deviation was 5.59%, 
while that of patient # 46 was 25.08%. 
 
Table 1: Percentage deviation dose calculated from 31 curative intent cervical cancer patients in 













% deviation of the 
dose from calculated 
dose 
Patient # 1 1.61 1.28 1.33 3.75 
Patient # 2 1.56 1.24 1.37 9.48 
Patient # 3 1.38 1.11 1.37 18.95 
Patient # 4 1.98 1.57 1.40 –12.14 
Patient # 5 2.25 1.68 1.42 –18.30 
Patient # 6 2.06 1.50 1.41 –6.38 
Patient # 7 1.70 1.36 1.37 0.73 
Patient # 8 1.80 1.34 1.30 –3.08 
Patient # 9 1.67 1.32 1.36 2.94 
Patient # 10 1.76 1.40 1.38 –1.45 
Patient # 11 1.70 1.27 1.37 7.30 
Patient # 12 1.72 1.36 1.37 0.73 
Patient # 13 1.77 1.42 1.39 –2.16 
Patient # 14 1.77 1.32 1.38 4.35 
Patient # 15 1.67 1.24 1.37 9.50 
Patient # 16 1.91 1.52 1.41 –8.03 
Patient # 17 2.03 1.45 1.43 –1.40 
Patient # 18 1.70 1.27 1.37 7.92 
Patient # 19 1.88 1.50 1.38 –8.69 
Patient # 20 1.70 1.35 1.37 1.45 
Patient # 21 1.64 1.31 1.36 3.72 
Patient # 22 1.70 1.35 1.37 1.99 
Patient # 23 1.68 1.25 1.38 9.42 
Patient # 24 1.67 1.35 1.38 2.17 
Patient # 25 1.75 1.41 1.38 –2.17 
Patient # 26 1.77 1.43 1.38 –3.62 
Patient # 27 1.57 1.27 1.35 5.93 
Patient # 28 1.86 1.50 1.37 –9.49 
Patient # 29 1.71 1.26 1.39 9.35 
Patient # 30 1.69 1.45 1.38 –5.07 
Patient # 31 1.90 1.53 1.38 –10.87 
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Table 2: Percentage dose deviation observed from expected dose in 9 cervical cancer patients 
treated with palliative intent 





dose  (Gy) 
% deviation of measured 
from prescribe dose 
Patient # 32 8.68 6.37 6.89 7.50 
Patient # 33 8.50 6.24 6.89 9.40 
Patient # 34 7.73 5.68 6.85 17.21 
Patient # 35 8.32 6.28 7.04 10.83 
Patient # 36 9.15 6.72 6.94 3.23 
Patient # 37 8.35 6.22 6.89 9.24 
Patient # 38 8.85 6.41 6.89 7.08 
Patient # 39 7.63 5.84 6.66 12.47 
Patient # 40 8.21 6.61 6.85 3.56 
 
Table 3: Percentage deviation dose calculated from 12 curative intent cervical cancer patients 
in 25 fractions 
Patient ID First fraction 
diode dose 
reading (Gy) 
Total entrance dose 
for 25 fractions 
(Gy) 
Total calculated 
dose for 25 
fractions  (Gy) 
% deviation of 
the total doses 
Patient # 41 1.69 32.78 34.48 4.94 
Patient # 42 1.6 30.18 34.48 12.47 
Patient # 43 1.53 28.03 35.71 21.51 
Patient # 44 1.7 33.81 34.25 1.27 
Patient # 45 1.79 32.78 34.72 5.59 
Patient # 46 1.5 25.64 33.33 25.08 
Patient # 47 1.85 36.87 34.96 -5.45 
Patient # 48 1.49 27.61 33.56 17.73 
Patient # 49 2.45 35.67 35.46 -0.59 
Patient# 50 1.63 32.66 34.25 4.64 
Patient# 51 1.71 30.75 34.25 10.23 
Patient# 52 1.88 40.49 35.71 -13.37 
 
Discussion 
In practice, in-vivo dosimetry of the 
measured dose from prescribed has been used 
as method to detect errors in radiation therapy 
and to assess the dose delivery accuracy of 
radiotherapy machine (Pokoo et al. 2015, 
Tunio et al. 2011, Yusuph et al. 2016, 
Rodríguez et al. 2008). As indicated in Table 
1, only 15 patients (48%) out of 31 had 
deviations within the acceptable range of ± 
5% in the first fraction of their measurements. 
In comparison, a study conducted by Yusuph 
et al. (2016) at ORCI to assess dose delivery 
accuracy of the same tele-cobalt machine for 
breast cancer patients treated with curative 
intent, 32 out of 50 patients (64%) were 
reported to have percentage deviation within 
the range of ± 5% in the first fraction. Since 
both studies used ORCI’s Theratron Equinox 
80, it is evident that the higher accuracy 
reported in the previous studies may not be 
attributed exclusively to the radiotherapy 
machine. The observed difference in dose 
deviations is most likely attributed to other 
causes including patient related factors as 
already pointed out by other authors 
(Thwaites 2013, Pokoo et al. 2015). Since it is 
unlikely that the machine is the main source 
of errors, there is an urgent need to investigate 
the sources responsible for such large 
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deviations of the measured from prescribed 
doses. With the information gathered from 
such investigations, it would be possible to 
specify more precisely the purpose of 
investigating dose delivery accuracy using a 
single dose fraction. This requirement is not 
essential in the palliative treatment, especially 
when negative (under dose) errors are not 
observed as was the case in this study.  
In-vivo dosimetry for cervical cancer 
patients who received a palliative treatment 
was also done and the results of percentage 
deviations between prescribed and delivered 
dose are presented in Table 2. Since none of 
the 9 palliative patients was under dose, the 
observed positive percentage dose deviations 
could be beneficial knowing that these were 
palliative patients who need this opportunity 
for reducing suffering and death from cervical 
cancer in Tanzania. Beside these results, it is 
also very important to improve screening 
process and early detection to reduce 
morbidity and mortality from cervical cancer 
in Tanzania. 
From table 3, it can be observed that 2 
out of 12 patients had negative deviations 
outside the specified range, while 6 patients 
had positive deviations outside this range. 
Higher deviations in this group of patients 
could be due to planning calculations, patient 
movement during treatment, wrong patient 
set-up and other machine related factors like 
fluctuation of power. According to ICRU 
report 50 specifications (Landberg et al. 1993, 
ICRU 2016), more than 50% of the patients 
treated would not be cured. Incidentally, this 
value corresponds to below 40% of curability 
of cancer of the cervix already reported in the 
literature for the sub-Saharan countries 
(Thwaites 2013, Maranga et al. 2013, Nelson 
et al. 2016). Curability could be also 
influenced by dose prescription which does 
not specify the amount of dose delivered to 
the tumour mass. Since the specification of 
dose delivery accuracy is related to the dose 
delivered to the tumour mass, there is a need 
for dose prescription to be modified to have a 
closer relationship to the dose requirement for 
curability. In this case, investigations of the 
factors responsible for dose deviations 
associated with dose planning based on 2D 
images are urgently needed for subsequent 
development of methods to improve dose 
delivery accuracy. However, unless the 
prescribed dose related to the dose needed to 
eradicate the tumour mass, dose delivery 




In this study, the determination of dose 
deviations between prescribed and delivered 
doses was done using a diode detector. A high 
degree of deviation was observed in some 
patients. This requires the determination of 
prescription dose and treatment protocol to be 
modified to have a closer relationship to the 
dose requirement for curability for patients 
treated using Equinox 80 tele-cobalt machine 
at ORCI.  
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